Human Immunodeficiency Virus Type 1 Hypersusceptibility to Amprenavir In Vitro Can Be Associated with Virus Load Response to Treatment In Vivo
Open Access
- 15 December 2001
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 33 (12) , 2075-2077
- https://doi.org/10.1086/324510
Abstract
The human immunodeficiency virus type 1 protease mutation N88S, which is occasionally selected by treatment with nelfinavir or indinavir, confers hypKeywords
This publication has 6 references indexed in Scilit:
- Prevalence of Genotypic Resistance among Antiretroviral Drug-Naive HIV-1-Infected Patients in BelgiumAntiviral Therapy, 2001
- In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632Antimicrobial Agents and Chemotherapy, 2000
- A Mutation in Human Immunodeficiency Virus Type 1 Protease, N88S, That Causes In Vitro Hypersensitivity to AmprenavirJournal of Virology, 2000
- Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavirAIDS, 1999
- Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitorJournal of Virology, 1996